Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment :: Results from the CLEAR study

Diamant Thaçi; Lluís. Puig Sanz; K. Reich; T. F. Tsai; S. Tyring; K. Kingo; M. Ziv; A. Pinter; R. Vender; A. Lacombe; Shang Xia; V. Bhosekar; I. Gilloteau; A. Guana; Andrew Blauvelt

doi:10.1016/j.jaad.2019.04.045

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study

Diamant Thaçi, Lluís. Puig Sanz, K. Reich, T. F. Tsai, S. Tyring, K. Kingo, M. Ziv, A. Pinter, R. Vender, A. Lacombe, Shang Xia, V. Bhosekar, I. Gilloteau, A. Guana, Andrew Blauvelt

Departament de Medicina

Novartis Pharma AG

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

16 Cites (Scopus)

Idioma original	Anglès
Pàgines (de-a)	1405-1409
Nombre de pàgines	5
Revista	Journal of the American Academy of Dermatology
Volum	81
Número	6
DOIs	https://doi.org/10.1016/j.jaad.2019.04.045
Estat de la publicació	Publicada - 2019

Accés al document

10.1016/j.jaad.2019.04.045

https://ddd.uab.cat/record/222744

Com citar-ho

Thaçi, D., Puig Sanz, L., Reich, K., Tsai, T. F., Tyring, S., Kingo, K., Ziv, M., Pinter, A., Vender, R., Lacombe, A., Xia, S., Bhosekar, V., Gilloteau, I., Guana, A., & Blauvelt, A. (2019). Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study. Journal of the American Academy of Dermatology, 81(6), 1405-1409. https://doi.org/10.1016/j.jaad.2019.04.045

@article{d2c535cc6e38442e82a0f623360c21b9,

title = "Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment :: Results from the CLEAR study",

author = "Diamant Tha{\c c}i and {Puig Sanz}, Llu{\'i}s. and K. Reich and Tsai, {T. F.} and S. Tyring and K. Kingo and M. Ziv and A. Pinter and R. Vender and A. Lacombe and Shang Xia and V. Bhosekar and I. Gilloteau and A. Guana and Andrew Blauvelt",

year = "2019",

doi = "10.1016/j.jaad.2019.04.045",

language = "English",

volume = "81",

pages = "1405--1409",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "6",

}

Thaçi, D, Puig Sanz, L, Reich, K, Tsai, TF, Tyring, S, Kingo, K, Ziv, M, Pinter, A, Vender, R, Lacombe, A, Xia, S, Bhosekar, V, Gilloteau, I, Guana, A & Blauvelt, A 2019, 'Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study', Journal of the American Academy of Dermatology, vol. 81, núm. 6, pàg. 1405-1409. https://doi.org/10.1016/j.jaad.2019.04.045

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study. / Thaçi, Diamant; Puig Sanz, Lluís.; Reich, K. et al.
In: Journal of the American Academy of Dermatology, Vol. 81, Núm. 6, 2019, pàg. 1405-1409.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment :

T2 - Results from the CLEAR study

AU - Thaçi, Diamant

AU - Puig Sanz, Lluís.

AU - Reich, K.

AU - Tsai, T. F.

AU - Tyring, S.

AU - Kingo, K.

AU - Ziv, M.

AU - Pinter, A.

AU - Vender, R.

AU - Lacombe, A.

AU - Xia, Shang

AU - Bhosekar, V.

AU - Gilloteau, I.

AU - Guana, A.

AU - Blauvelt, Andrew

PY - 2019

Y1 - 2019

U2 - 10.1016/j.jaad.2019.04.045

DO - 10.1016/j.jaad.2019.04.045

M3 - Article

C2 - 31399223

SN - 0190-9622

VL - 81

SP - 1405

EP - 1409

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 6

ER -

Thaçi D, Puig Sanz L, Reich K, Tsai TF, Tyring S, Kingo K et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study. Journal of the American Academy of Dermatology. 2019;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045